In Pilot, Team at Thomas Jefferson University Tests 454 GS Junior for Cancer Mutational Profiling | GenomeWeb

This story was originally published May 15.

Testing the waters for how next-generation sequencing could be used to guide individual therapy selection in cancer, researchers at Thomas Jefferson University have conducted a proof-of-principle study in colorectal adenocarcinoma using the 454 GS Junior.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.